Date: 2015-11-10
Type of information: Collaboration agreement
Compound: Multimaging™ services
Company: Imabiotech (France) Galderma (Switzerland)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism: Multimaging™ is a combination of imaging techniques (Quantitative MALDI imaging, staining, immune-staining) associated with dedicated software. This platform has the capability to jointly study quantitatively the distribution of analytes at a cellular level. It can be used during drug discovery and development, resulting in a better and faster drug selection for clinical phase.
Disease:
Details: * On November 10, 2015, Galderma, a leading pharmaceutical company in dermatology, and Imabiotech, a french CRO specialized in Mass Spectrometry Imaging, announced that Galderma has chosen ImaBiotech to support their drug development with innovative Multimaging™ services. Galderma has chosen ImaBiotech’s Multimaging™ services to combine and accelerate its drug pharmacokinetic, pharmacology, toxicology and formulation phases. Multimaging™ is a combination of imaging techniques (Quantitative MALDI imaging, staining, immune-staining) associated with dedicated software. This platform has the capability to jointly study quantitatively the distribution of analytes at a cellular level. It can be used during drug discovery and development, resulting in a better and faster drug selection for clinical phase. Galderma is interested in the capabilities of ImaBiotech’s MALDI imaging platform and would benefit from the Multimaging™ services to support their drug investigations. ImaBiotech will provide analysis of Galderma samples to investigate drug, metabolites and biomarker distribution quickly and efficiently.
Financial terms:
Latest news:
